198 related articles for article (PubMed ID: 10490989)
1. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
Ahuja SS; Reddick RL; Sato N; Montalbo E; Kostecki V; Zhao W; Dolan MJ; Melby PC; Ahuja SK
J Immunol; 1999 Oct; 163(7):3890-7. PubMed ID: 10490989
[TBL] [Abstract][Full Text] [Related]
2. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-gamma and IL-12.
Ahuja SS; Mummidi S; Malech HL; Ahuja SK
J Immunol; 1998 Jul; 161(2):868-76. PubMed ID: 9670965
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis.
Shao C; Qu J; He L; Zhang Y; Wang J; Zhou H; Wang Y; Liu X
Genes Immun; 2005 Mar; 6(2):103-14. PubMed ID: 15674391
[TBL] [Abstract][Full Text] [Related]
4. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
5. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
Agallou M; Margaroni M; Karagouni E
Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
7. CD40 expression levels modulate regulatory T cells in Leishmania donovani infection.
Martin S; Agarwal R; Murugaiyan G; Saha B
J Immunol; 2010 Jul; 185(1):551-9. PubMed ID: 20525887
[TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis.
Ghosh M; Pal C; Ray M; Maitra S; Mandal L; Bandyopadhyay S
J Immunol; 2003 Jun; 170(11):5625-9. PubMed ID: 12759442
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
Agallou M; Smirlis D; Soteriadou KP; Karagouni E
Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
[TBL] [Abstract][Full Text] [Related]
11. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
12. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
Tewary P; Saxena S; Madhubala R
Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
[TBL] [Abstract][Full Text] [Related]
15. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
16. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.
Schleicher U; Liese J; Knippertz I; Kurzmann C; Hesse A; Heit A; Fischer JA; Weiss S; Kalinke U; Kunz S; Bogdan C
J Exp Med; 2007 Apr; 204(4):893-906. PubMed ID: 17389237
[TBL] [Abstract][Full Text] [Related]
17. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
[TBL] [Abstract][Full Text] [Related]
18. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
19. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
20. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo.
Mejri N; Brossard M
Int Immunol; 2007 Apr; 19(4):535-43. PubMed ID: 17344202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]